Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 1, 2005, Pages 85-92

  Murphy, Barbara A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Head and neck cancer; Irinotecan; Radiotherapy; Topoisomerase I inhibitors; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CETUXIMAB; CISPLATIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEFITINIB; HYDROXYUREA; IRINOTECAN; METHOTREXATE; PACLITAXEL; RADIOSENSITIZING AGENT; TOPOTECAN; VINCRISTINE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME STRUCTURE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DNA REPLICATION; DNA TRANSCRIPTION; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; INFECTION; METASTASIS; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; RECURRENT CANCER; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE I; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; TOPOTECAN;

EID: 12744272174     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.1.85     Document Type: Review

References (51)

1. Cancer Facts and Figures 2000. American Cancer Society, Atlanta GA, USA (2000).
2. FORASTIERE A, KOCH W, TROTTI A, SIDRANSKY D: Medical Progress: head and neck cancer. N. Engl. J. Med. (2001) 345 1890-1900.
3. LAMONT EB, VOKES EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol. (2001) 2:261-269.
4. GILBERT J, FORASTIERE AA: Organ preservation trials for laryngeal cancer. Otolaryngol. Clin. North Am. (2002) 35 1035-1054.
5. SNIEZEK JC: Local treatment modalities for recurrent cancer of the head and neck. In: Atlas of Cancer. M Markman (Ed.), Lippincott Williams and Wilkins (2003):28-31.
6. DAVIDSON J, KEANE T, BROWN D et al.: Surgical salvage of oral and oraopharyngeal cancer recurring after radical radiotherapy. Arch. Otolaryngol. Head Neck Surg. (1997) 123:420-424.
7. PACHECO-OJEDA L, MARANDAS P, JULIERON M et al.: Salvage surgery by composite resection for epidermoid carcinoma of the tonsillar region. Arch. Otolaryngol. Head Neck Surg. (1992) 118 181-184.
8. STEVENS KR, BRITSCH A, MOSS WT: High-dose reirradiation of the head and neck cancer with curative intent. Int. J. Radiation Oncol. Biol. Phys. (1994) 29:687-698.
9. KAO J, GAROFALO ML, MILANO MT et al.: Re-irradiation of recurrent and primary head and neck malignancies. Cancer Treat. Rev. (2003) 29:21-30.
10. SPENCER SA, HARRIS J, WHEELER PH et al.: RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-flurouracil in patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51:1299-3004.
11. COOPER JS, PAJAK T, FORASTIERE AA et al.: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N. Engl. J. Med. (2004) 350 1937-1941.
12. BERNIER J, BOMERGE C, OZSAHIN M et al.: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. (2004) 350:1798-1804.
13. PACAGNELLA A, ORLANDO A, MARCHIORI C et al.: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the gruppo di studio sui Tumori della Testa e del Collo. J. Natl. Cancer Inst. (1994) 86:265-272.
14. MURPHY BA: Metastatic and recurrent head and neck cancer: treatment and outcomes. In: Atlas of Cancer. M Markman (Ed.), Lippincott Williams and Wilkins (2003):36.
15. TRIGO J, HITT R, KORALEWSKI P et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCHHN): results of a Phase II study. Proc. Am. Soc. Clin. Oncol. (2004) 23:5580.
16. COHEN EE, ROSEN F, STADLER WM et al.: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2003) 21:1980-1987.
17. FORASTIERE AA, LEONG T, ROWINSY E et al.: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Group Study E1393. J. Clin. Oncol. (2001) 19:1088-1095.
18. MURPHY BA, LI Y, CELLA D et al.: Phase III study comparing cisplatin and 5-flurouracil versus cisplatin and paclitaxel in metastatic/recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 894).
19. WANG JC: DNA Topoisomerases. Annu. Rev. Biochem. (1996) 65:635-692.
20. GUPTA M, FUJIMORI A, POMMIER Y: Eucaryotic DNA topoisomerases I. Biochim. Biophys. Acta (1995) 1262:1-14.
21. POURQUIRE P, PILON AA, KOHLHAGEN G, MAZUMDER A, SHARMA A, POMMIER Y: Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. J. Bio. Chem. (1997) 272:26441-26447.
22. ROTHENBERG M: Topoismerase I inhibitors: review and update. Ann. Oncol. (1997) 8:837-855.
23. ARGIRIS A, MURREN JR: Clinical use of the camptothecins at year 2000. PPO Updates (2000) 14:1-15.
24. ROBERT F, SOONG S, WHEELER RH: A Phase II study of topotecan in patients with recurrent head and neck cancer. Am. J. Clin. Oncol. (1997) 20:298-302.
25. SMITH RE, LEW D, RODRIGUEZ GI et al.: Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest. New Drugs (1996) 14 403-407.
26. MURPHY BA, LEONG T, BURKEY B, LANGER C, FORASTIERE A: Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Am. J. Clin. Oncol. (2001) 24:64-66.
27. HADDAD RI, VAN ECHO DA: Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother. Pharmacol. (2003) 52:303-306.
28. MURPHY BA, CMELAK A, BURKEY B et al.: Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology (2001) 15:48-52.
29. KANO Y, SUZUKI K, AKUTSU M et al.: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer. (1992) 50:604-610.
30. KUDOH S, TAKADA S, MASUDA N et al.: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenographs. Jpn. J. Cancer Res. (1993) 84:203-207.
31. JAGASIA MH, LANGER CJ, JOHNSON DH et al.: Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter Phase II study. Clin. Cancer Res. (2001) 7:68-73.
32. IKPEAZU CV, MURPHY BA, KISH B et al.: Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck (RMHNC). Proc. Am. Soc. Clin. Oncol. (2004) 23:5580.
33. FORASTEIERE AA, URBA SG: Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin. Oncol. (1995) 22:24-27.
34. KANO Y, AKUTSU M, TSUNODA S et al.: In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother. Pharmacol. (1998) 42:91-98.
35. MURREN J, BLUM K, GALLIPOLI MA, RICH R: Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule. Oncology (2001) 51:25-30.
36. LAD T, ROSEN B, BROCKSTEIN R et al.: Phase II trial of 9-aminocamptothecin (9AC/DMA) in patients with advanced squamous cell head and neck cancer. Proc. Am. Sec. Clin. Oncol. (1998) 17 392a.
37. LAMOND JP, WANG M, KINESELLA TJ, BOOTHMAN DA: Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Int. J. Radiat. Oncol. Biol. Phys. (1996) 36:369-376.
38. CHEN AY, OKUNIEFF P, POMMIER Y, MITCHELL JB: Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. (1997) 57:529-536.
39. MIYAMATO S, HUANG TT, WUERZBERGER-DAVIS S et al.: Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann. NY Acad. Sci. (2000) 922 274-292.
40. LAMOND JP, WANG M, KINESELLA TJ, BOOTHMAN DA: Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. (1996) 36:361-368.
41. TAMURA K, TAKDA M, KAWASW I et al.: Enhancement of tumor raido-response by irinotecan in human lung tumor xenographs. Jpn. J. Cancer Res. (1997) 88:218-223.
42. BOOTHMAN DA, FUKUNAGA N, WANG M: Down-regualtion of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res. (1994) 54:4618-4626.
43. BOOTHMAN DA, PARDEE AB: Inhabition of radiation-induced neoplastic transformation by b-lapachone. Proc. Natl. Acad. Sci. (1989) 86:4963-4967.
44. BOOTHMAN DA, TRASK DK, PARDEE AB: Anticarcinogenic potential of DNA repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res. (1989) 49:605-612.
45. CHASTAGNER P, MERLIN JL, MARCHAL C et al.: In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice. Clin. Cancer Res. (2000) 6 3327-3333.
46. MATTERN MR, HOFMANN FL, MCCABE FL, JOHNSON RK: Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan. Cancer Res. (1991) 51:5813-5816.
47. CHOY H, MACRAE R: Irinotecan and radiation in combined-modality therapy for solid tumors. Oncology (2001) 15 22-28.
48. ILSON DH, BAINS M, KELSON D et al.: Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J. Clin. Oncol. (2003) 21:2926-2932.
49. FISHER B, SCOTT C, MACDONALD DR, CURRAN WJ: Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of radiation therapy Oncology Group Trial 9507. J. Clin. Oncol. (2001) 19:1111-1117.
50. SALAMA JK, HARAF DJ, STENSON K, VOKES E: Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU and hydroxyurea for patients with advanced and/or recurrent head and neck cancer: toxicity and outcome results. Proc. Amer. Soc. Clin. Oncol. (2004) 23 5561.
51. KOUKOURAKIS MI, BIZAKIS JG, SKOULAKIS CE et al.: Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer: a Phase I dose escalation study. Anticancer Res. (1999) 19:2305-2309.